Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients


Disclosures: This analysis was supported by funding from Bayer. J.A.A., E.I.N., S.J. and M.O.K. are employees of the Department of Pharmaceutical Biosciences, Uppsala University. A.S. and D.G. are employees of Bayer. J.A.A., E.I.N. and S.J. have received funding from Pfizer Limited, United Kingdom, for research in hemophilia (morocctocog alfa).

Contributions: M.O.K, J.A.A., E.I.N. and S.J. designed the analysis in conjunction with A.S. and D.G.; J.A.A. performed the analysis and wrote the manuscript; M.O.K., E.I.N. and S.J. reviewed and supervised the analysis and the manuscript preparation; A.S. and D.G. reviewed all steps of the analysis and the manuscript preparation.